Icatibant: Difference between revisions
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
(Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links) |
||
| Line 56: | Line 56: | ||
|format=broadtable | |format=broadtable | ||
|headers=plain | |headers=plain | ||
| | |mainlabel=- | ||
|sort=Has Indication | |sort=Has Indication | ||
|limit=50 | |limit=50 | ||
Revision as of 17:26, 20 March 2026
General
- Type: Bradykinin receptor antagonist
- Dosage Forms: 30mg
- Routes of Administration: Subcutaneous
- Common Trade Names: Firazyr
Adult Dosing
Hereditary angioedema
- 30mg subcutaneous x 1
- May repeat q6h if inadequate response/symptoms recur
- Max 90mg/24 hours
Pediatric Dosing
not available (8/2015)
Special Populations
- Pregnancy Rating: C
- Lactation risk: safety unknown
- Renal Dosing
- Hepatic Dosing
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Caution if acute MI
- Caution if unstable angina
- Caution if recent stroke
Common
- Injection site reaction
- Dizziness
- Fever
- Increased LFTs
Pharmacology
- Half-life: 1.4h
- Metabolism: Proteolytic degradation
- Excretion: Urine 10% unchanged
- Mechanism of Action: selectively antagonizes bradykinin B2 receptor
Comments
- NEJM article 1/2015 randomized 27 people with ACEi induced angioedema to icatibant vs std therapy (Prednisone 500mg + Clemastine 2mg) looking at time to resolution.
RESULTS- significantly shorter (8 hrs vs 27.1 hrs) in icatibant group.
- Cost according to Goodrx= $9,000/dose (on 8/7/2015)
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Angioedema | 30 mg SC | Bradykinin B2 receptor antagonist (HAE/ACE-I angioedema) | SC | Adult |